1. Bioavailability studies submitted in NDAs or INDs: general considerations Publication: Silver Spring, MD : Center for Drug Evaluation and Research, April 2022 Subject(s): Biological AvailabilityClinical Trials as TopicDrug ApprovalDrug EvaluationInvestigational New Drug ApplicationUnited StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration
